These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

962 related items for PubMed ID: 18278552

  • 1. Integrated gene expression profile predicts prognosis of breast cancer patients.
    Li LF, Xu XJ, Zhao Y, Liu ZB, Shen ZZ, Jin WR, Shao ZM.
    Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
    Holm NT, Abreo F, Johnson LW, Li BD, Chu QD.
    Breast Cancer Res Treat; 2009 Jan 12; 113(2):293-9. PubMed ID: 18270814
    [Abstract] [Full Text] [Related]

  • 6. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.
    Breast Cancer Res Treat; 2009 Jan 12; 113(2):275-83. PubMed ID: 18311582
    [Abstract] [Full Text] [Related]

  • 7. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Population-based molecular prognosis of breast cancer by transcriptional profiling.
    Ma Y, Qian Y, Wei L, Abraham J, Shi X, Castranova V, Harner EJ, Flynn DC, Guo L.
    Clin Cancer Res; 2007 Apr 01; 13(7):2014-22. PubMed ID: 17404081
    [Abstract] [Full Text] [Related]

  • 10. Evidence for a transcriptional signature of breast cancer.
    Feng Y, Li X, Sun B, Wang Y, Zhang L, Pan X, Chen X, Wang X, Wang J, Hao X.
    Breast Cancer Res Treat; 2010 Jul 01; 122(1):65-75. PubMed ID: 19728083
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. p53 as a specific prognostic factor in triple-negative breast cancer.
    Chae BJ, Bae JS, Lee A, Park WC, Seo YJ, Song BJ, Kim JS, Jung SS.
    Jpn J Clin Oncol; 2009 Apr 01; 39(4):217-24. PubMed ID: 19304743
    [Abstract] [Full Text] [Related]

  • 13. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L.
    Breast Cancer Res Treat; 2008 Mar 01; 108(2):183-90. PubMed ID: 17468948
    [Abstract] [Full Text] [Related]

  • 14. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 01; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 15. [Prognostic molecular classification of breast cancers based on gene expression profiling].
    Feng YM, Li XQ, Sun BC, Gao XC, Gu L, Niu Y, Hao XS.
    Zhonghua Zhong Liu Za Zhi; 2006 Dec 01; 28(12):900-6. PubMed ID: 17533740
    [Abstract] [Full Text] [Related]

  • 16. Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
    Heikkinen T, Korpela T, Fagerholm R, Khan S, Aittomäki K, Heikkilä P, Blomqvist C, Carpén O, Nevanlinna H.
    Breast Cancer Res Treat; 2013 Aug 01; 141(1):79-88. PubMed ID: 23974830
    [Abstract] [Full Text] [Related]

  • 17. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
    Litviakov NV, Garbukov EIu, Slonimskaia EM, Tsyganov MM, Denisov EV, Vtorushin SV, Khristenko KIu, Zav'ialova MV, Cherdyntseva NV.
    Vopr Onkol; 2013 Aug 01; 59(3):334-40. PubMed ID: 23909034
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
    Yang Q, Sakurai T, Yoshimura G, Suzuma T, Umemura T, Nakamura M, Nakamura Y, Mori I, Kakudo K.
    Oncol Rep; 2003 Aug 01; 10(1):121-5. PubMed ID: 12469156
    [Abstract] [Full Text] [Related]

  • 19. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
    Mook S, Knauer M, Bueno-de-Mesquita JM, Retel VP, Wesseling J, Linn SC, Van't Veer LJ, Rutgers EJ.
    Ann Surg Oncol; 2010 May 01; 17(5):1406-13. PubMed ID: 20094918
    [Abstract] [Full Text] [Related]

  • 20. Rho GDP dissociation inhibitor alpha expression correlates with the outcome of CMF treatment in invasive ductal breast cancer.
    Ronneburg H, Span PN, Kantelhardt E, Dittmer A, Schunke D, Holzhausen HJ, Sweep FC, Dittmer J.
    Int J Oncol; 2010 Feb 01; 36(2):379-86. PubMed ID: 20043072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.